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Summary The growth inhibitory effects of all-trans and 13-cis retinoic acid (RA) and of the synthetic
retinoids TTNPB, TTNPB-ethylester and TTNN were studied on seven human epithelial ovarian cancer cell
lines and one ovarian teratocarcinoma cell line. Six of seven ovarian adenocarcinoma cell lines were inhibited
in their growth by RA and by synthetic retinoids in a dose dependent manner. No response to these
substances was observed for the ovarian teratocarcinoma cell line. The knowledge that RA and retinoids exert
their action on the cells via nuclear receptors led us to examine the expression of RAR-a, - ,B and - mRNA
by these cell lines by polymerase chain reaction following reverse transcription. All cell lines expressed RAR-x
and - mRNA and six of the eight cell lines were found to express additionally RAR-P mRNA, among them
the ovarian teratocarcinoma cell line. Our data indicate that there was no direct association between the
presence of RAR subtype transcripts and the response to retinoids in ovarian cancer cell lines.
Retinoic acid (RA) is a morphogenic compound involved in
vertebrate development (Eichele, 1989) and it plays a major
role in epithelial cell growth and cellular differentiation
(Sporn et al., 1984). RA induces differentiation of mouse
embryonal carcinoma cells in vitro and influences the
development of the regenerating amphibian limb (for review
see de Luca, 1991).
It has also been shown that retinoids cause growth inhibi-
tion in many hyperproliferating cell lines, a feature that
makes the compounds of fundamental interest as antitumour
agents. Retinoids prevent the development of cancer of the
skin and are effective as agents in the treatment of human
premalignant and malignant cutaneous disorders (Lippman
& Meyskens, 1989). In addition, retinoids are successfully
used in the therapy of the acute promyelocytic leukaemia
(Meng-er et al., 1988).
Several intracellular proteins interacting with RA have
been identified, such as the cellular retinoic acid binding
protein (CRABP) and the nuclear retinoic acid receptors
(RARs). Three RAR subtypes RAR-a, -P and -y have been
identified so far (Petkovich et al., 1987; Giguere et al., 1987;
Benbrook et al., 1988; Brand et al., 1988; Krust et al., 1989).
The RARs belong to the family of steroid- and thyroid
hormone receptors and act as transcriptional enhancer fac-
tors. The binding of RARs to specific response elements
leads to self-modulation of their transcription (Umesono et
al., 1988; Glass et al., 1989; de The et al., 1990). In addition,
another subfamily of nuclear receptors (termed RXRs) which
might mediate some of the effects of RA or its different
metabolites, has been described (Mangelsdorf et al., 1990; Yu
et al., 1991; Heyman et al., 1992). It has also been shown
that RA and synthetic retinoids have different receptor
affinities and each receptor has a different potency in stimu-
lating transcription of target genes (Astrom et al., 1990;
Graupner et al., 1991; Delelcuse et al., 1991). Nevertheless,
the exact mechanism of action by which RA and retinoids
work is still to be elucidated.
In this report we studied the effects of RA and synthetic
retinoids on the growth of several human ovarian cancer cell
lines in vitro and the expression of RAR-xo, -P and
-v mRNA
in these cell lines, both without and with exposition to RA.
Materials and methods
Cell culture
The ovarian adenocarcinoma cell lines HOC-7 and HEY
were a generous gift from Dr R. Buick (Ontario Cancer
Institute, Toronto, Canada), H134 was kindly donated to us
by Dr H. Broxterman (Free University Hospital, Amsterdam,
NL), TR 170 was a gift from Dr B. Hill (Imperial Cancer
Research Funds, London, UK). The ovarian adenocar-
cinoma cell lines HTB 77 (SK-OV-3), HTB 75 (CaOV-3),
NIH:OVCAR-3 and the ovarian teratocarcinoma cell line
CRL 1572 (PA-1) were received from the American Tissue
Type Culture Collection (ATCC, Rockville, MD, USA). All
cell lines were cultivated in a-MEM (Gibco, Scotland) supp-
lemented with 10% heat-inactivated foetal calf serum (Gibco,
Scotland) and were maintained in an humidified 5% CO2
atmosphere at 37°C. Cultures were refed after 4 days and
passaged weekly 1:5-1:10.
All cells were used within 30 passages from the original
stock.
Tests for mycoplasma contamination were negative (DAPI,
Boehringer Mannheim, Germany).
Retinoids
All-trans RA, 13-cis RA, (E)-4-[2-(5,6,7,8-tetrahydro-5,5,8,8,-
tetramethyl-2-naphthalenyl)- 1-propenyl] benzoic acid
(TTNPB), (E)-4-[2-(5,6,7,8-tetrahydro-5,5,8,8,-tetramethyl-2-
naphthalenyl)-1-propenyl] benzoic acid ethylester (TTNPB-
ethylester) and 5',6',7',8'-tetrahydro-5',5',8',8'-tetramethyl-
[2,2'-binaphthalene]-6-carboxylic acid (TTNN) were donated
to us by Dr J. Eliason (Nippon Roche Research Center,
Kamakura, Japan). 10-2 M, 10-4 M and 10-6 M stock solu-
tions of each retinoid were prepared in DMSO. For cultures
stock solutions were diluted 1:1000 in medium containing the
cell suspensions.
Dose response curves
Dose response curves were evaluated using the Cell Titer
96TM Non-Radioactive Cell Proliferation/Cytotoxicity Assay
(Promega, WI, USA) with a minor modification.
0.8-3.0 x 104cells ml-' were seeded in 96 well plates. Ali-
quots of 100fil of the cell suspension were pipetted into each
well. The final retinoid concentrations in this assay used were
10 fLM, 0.1I4M and 1.0 nM. As control cells were grown both
in 0.1% DMSO as solvent and without DMSO. On day 5
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each well was incubated with 15 tlI dye solution 1:3 diluted
for 4 h at 37°C in an humidified 5% CO2 atmosphere. Then
wells were incubated with 100 p1 solubilisation solution for
24 h in an humidified chamber. Absorbance was measured at
570 nm in an Anthos ELISA reader 2001 with a reference
wavelength of 690 nm. Each plate contained a serial dilution
of a cell suspension with defined viable cell count. Dose
response was estimated in percent viable cells of control.
RNA isolation and reverse transcription
Total cellular RNA was isolated by the guanidinium
isothiocyanate procedure (Chomczynski & Sacchi, 1987).
cDNA was synthetisised using the cDNA cycle kit provided
from In Vitrogen (In Vitrogen Corp., San Diego, CA, USA).
cDNA was synthetisised with 1 jsg random primer and five
units AMV reverse transcriptase; S gLg total RNA was used as
template. As negative control total RNA was treated in the
same way without adding reverse transcriptase.
Polymerase chain reaction amplification
First amplification:
Primer sequences were as follows:
RAR-a sense 5'-GCCCAAGCCCGAGTGCTC-3',
antisense 5'-CTACAGCTGCCTGGCGGG-3';
RAR-P sense 5'-AGGAGACTTCGAAGCAAG-3',
antisense 5'-GTCAAGGGTTCATGTCCTTC-3';
RAR-y sense 5'-GGAAGAAGGGTCACCTGA-3',
antisense 5'-CGGCGCCGGGCGTACAGC-3'.
Table I details the specific oligonucleotide regions used.
cDNA was amplified in a 50 1l reaction mix. Reaction mix
was composed of 21gI cDNA (equivalent to 500ng RNA),
2.5 gil dNTP (Sigma, St. Louis, MO, USA) (5 mM each
dATP, dCTP, dGTP and dTTP), 2.5 gIl each of 5' and 3'
sequence primers (10 pmol/lil each) and 5 ,il 10 x buffer
(100 mM Tris-HCl, pH 8.3, 500 mM KCI, 15 mM MgCl2,
0.1% gelatin), 2.5 gIl DMSO and brought with water to a
final of 50 gil. cDNA was then heat denaturated at 95°C for
5 min. Then the mix was cooled down to 80°C and 1 Ail (2.5
units) Taq polymerase (Perkin Elmer Cetus, Norwalk, CT,
USA) were pipetted into each tube. PCR was performed in a
Perkin Elmer Cetus Thermal Cycler 9600 for 45 cycles. A
cycle profile consisted of 40 s at 94°C for denaturation, 70 s
at 72°C for annealing and extension (RAR-io), 30 s at 60'C
for annealing and 60 s at 72°C for extension (RAR-P and
RAR-'y) with an extra 5 min extension for the last cycle. As
negative controls H20 only and total RNA were amplified
under the same conditions.
Semi-nested PCR:
Primer sequences were as follows:
A
TG C
RAR-a, -,, -y sense 5'-CCTCGCTCTGCCAGCTGGG-3';
RAR-a antisense 5'-CTACAGCTGCCTGGCGGG-3';
Table I Oligonucleotide primers
Location of oligonucleotide in nucleotide sequence of cDNA
First amplification
Fragment size
RNA transcript S'-Oligonucleotide 3'-Oligonucleotide (base pairs)
RAR-oc 733-750 1560-1543 827
RAR-P 822-839 1593-1574 771
RAR-y 715-732 1302-1285 587
Semi-nested PCR
Fragment size
RNA transcript 5'-Oligonucleotide 3'-Oligonucleotide (base pairs)
RAR-a 825-843 1560-1543 735
RAR-13 921-939 1593-1574 672
RAR-y 804-822 1302-1285 498
RAR-,B antisense 5'-GTCAAGGGTTCATGTCCTTC-3';
RAR-y antisense 5'-CGGCGCCGGGCGTACAGC-3'.
Seminested PCR was performed as described above. For
amplification 1 ,ul of each PCR-product was pipetted to 49 ILI
reaction mix. Table I details the specific oligonucleotide
regions used. Semi-nested PCR was performed for 25 cycles
for RAR-i and -y and for 15 cycles for RAR-P. A cycle
profile consisted of 30s at 94°C for denaturation, 30 s at
62'C for annealing and 30 s at 72°C for extension with an
extra 5 min extension for the last cycle. Electrophoresis of
10 1il reaction mix was performed on a 2% agarose gel
containing ethidium bromide. As size marker a 100 base
pairs DNA-ladder (Gibco, Scotland) was used.
Restriction endonuclease digestion ofPCR products
Amplified fragments were ethanol precipitated, dried and
redissolved in 10g water. To each fragment 2 gd of 1Ox
digestion buffer was pipetted and brought with water up to a
total of 20gLd. 1 -2gil of the specific enzymes (10 units) were
given to each tube and incubated at appropriate temperatures
for 3 h. Enzymes and buffers were purchased from New Eng-
land Biolabs (New England Biolabs, Beverley, MA, USA).
Results
Dose response curves
The dose dependent growth inhibition by all-trans RA, 13-cis
RA and the synthetic retinoids TTNPB, TTNPB-ethylester
and TTNN was determined using a non-cytotoxic colorimet-
ric cell proliferation assay based on the reduction of a tetra-
zolium salt to the insoluble formazan (Mosmann, 1983). The
cell numbers in percent of control (0.1% DMSO as solvent)
at different concentrations of each retinoid are shown in
Table II.
All substances tested exhibited growth inhibiting effects on
the human epithelial ovarian cancer cell lines, but not on the
ovarian teratocarcinoma cell line PA-1. The growth of the
cell lines HEY, H134, HTB 77, HTB 75, OVCAR-3 and TR
170 was inhibited by all-trans RA and 13-cis RA at different
degrees. The synthetic retinoids TTNPB, TTNPB-ethylester
and TTNN affected the growth of these cell lines in a similar
mode; among them TTNPB-ethylester was identified as the
least effective substance. As prototype of a cell line with good
response to retinoids the dose response to retinoids of the cell
line H 134 is shown in Figure la. In contrast thereto, only a
weak response to RA and to synthetic retinoids was observed
for the cell line HOC-7 as illustrated in Figure lb. The
human ovarian teratocarcinoma cell line PA-1 was not
inhibited in its growth by any of the substances, except by
the highest concentration of 13-cis RA tested.
Due to the known growth inhibiting effects of DMSO on
proliferating cells a control culture without 0.1% DMSO was
used in each experiment. There was no growth reduction
exceeding more than 5% of control in the presence of 0.1%
DMSO.
Analysis ofPCRproducts
Total RNA was extracted from eight ovarian carcinoma cell
lines. RNAs were transcribed into cDNA and then amplified
using gene-specific primer pairs and polymerase chain reac-
tion methodology (Mullis & Faloona, 1987; Saiki et al.,
1988). The identity of the PCR products were confirmed with
three methods. First, a primary PCR product was amplified
from the target cDNA. The fragment sizes for RAR-x, -P
and -y are illustrated in Table I. As negative control total
RNA was amplified under the same conditions to investigate
whether there was a contamination of chromosomal DNA in
the RNA preparation. Due to a minor homology of the three
receptor subtypes the primer pairs were located in the ligand
binding domain (region E) of the RARs. To confirm these532 H. HARANT et al.
Table II Percentage of viable cells of untreated control after 4 days exposure to retinoids. Values are means
of four separate experiments.
HOC-7 HEY H134 HTB 77 HTB 75 OVCAR-3 TR 170 PA-i
All-trans retinoic acid
control 100 100 100 100 100 100 100 100
I nM 77 82 61 76 77 70 100 114
0,1 M 80 62 40 55 65 51 93 132
10JM 75 47 39 44 56 40 62 86
13-cis retinoic acid
control 100 100 100 100 100 100 100 100
M nM 78 62 51 82 77 76 118 92
0, IJiM 83 70 52 59 70 67 79 130
10 PLM 76 45 40 36 53 40 43 53
TTNPBa
control 100 100 100 100 100 100 100 100
M nM 80 100 51 67 85 63 92 96
0, I LM 72 77 41 68 67 63 86 107
10JAM 10 41 37 35 39 50 49 89
TTNPB-ethylesterb
control 100 100 100 100 100 100 100 100
I nM 77 88 50 63 82 80 103 80
0,1 tM 75 72 44 65 98 66 98 113
10 LM 73 57 57 56 83 72 107 101
TTNNC
control 100 100 100 100 100 100 100 100
I nM 80 69 48 78 71 80 97 118
0,1 IM 84 54 43 72 62 69 92 151
10jM 84 59 52 41 26 66 57 119
a(E)-4-[2-(5,6,7,8-tetrahydro-5,5,8,8,-tetramethyl-2-naphthalenyl)-l-propenyl] benzoic acid. b(E)-4-[2-(5,6,7,8-
tetrahydro-5,5,8,8,-tetramethyl-2-naphthalenyl)-1-propenyl] benzoic acid ethylester. c5',6',7',8'-tetra-
hydro-5',5',8',8'-tetramethyl-[2,2'-binaphthalene]-6-carboxylic acid.
PCR products a semi-nested PCR was used as a second step.
For semi-nested PCR one slightly degenerated 5'-primer was
used for amplification of all three receptor subtypes due to
the high homology in this region. With 3'-primers already
used in the first PCR experiment three defined PCR products
for RAR-4o, -P and -- were amplified as shown in Table I.
Semi-nested PCR products were separated on a 2% agarose
gel as shown in Figures 2, 3 and 4. As negative control
amplified RNA samples were amplified under the same con-
ditions to confirm whether there were contaminations
between the two PCR experiments.
In a third step PCR products from the semi-nested experi-
ment were digested with specific restriction endonucleases.
The RAR-a PCR product was digested with Aval. Three
defined fragments (127, 237 and 371 base pairs) separated on
H 134
a 2% agarose gel are shown in Figure 5. Hinfl was chosen
for digestion of the RAR-P PCR product (47, 157 and 468
base pairs) as shown in Figure 6. BsmAI was used for
restriction analysis of the RAR-y PCR product. Three
defined fragments (37, 97 and 364 base pairs) separated on a
2% agarose gel are shown in Figure 7.
Expression ofRAR-a, -P and -y mRNA
In eight ovarian carcinoma cell lines, the epithelial ovarian
cancer cell lines HOC-7, HEY, H134, HTB 77, HTB 75,
OVCAR-3 and TR 170 and the ovarian teratocarcinoma cell
line PA-1 the expression of RAR mRNA was studied by
means of RT-PCR. For the analysis of RAR mRNA expres-
sion cells were cultivated in medium with and without 10pLM
a
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Figure 1 Dose response of the epithelial ovarian cancer cell line H134 a, and HOC-7 b. (1) all-trans retinoic acid, (2) 13-cis
retinoic acid, (3) (E)-4-[2-(5,6,7,8-tetrahydro-5,5,8,8,-tetramethyl-2-naphthalenyl)-l-propenyl] benzoic acid (TTNPB), (4) (E)-4-[2-
(5,6,7,8-tetrahydro-5,5,8,8,-tetramethyl-2-naphthalenyl)-l-propenyl] benzoic acid ethylester (TTNPB-ethylester) (5) 5',6',7',8'-
tetrahydro-5',5',8',8'-tetramethyl-[2,2'-binaphthalene]-6-carboxylic acid (TTNN).
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Figure 2 Semi-nested PCR products of RAR-a (735 bp) separated on a 2% agarose gel, stained with ethidiumbromide. a, HOC-7
(1), HEY (2), H134 (3), HTB 77 (4), 100 bp DNA ladder (5), HTB 75 (6), OVCAR-3 (7), TR 170 (8), PA-I (9). b, negative RNA
control: HOC-7, (1), HEY (2), H134 (3), HTB 77 (4), HTB 75 (5), 100 bp DNA ladder (6), OVCAR-3 (7), TR 170 (8), PA-i1 (9),
H20 (10). The DNA ladder (ordinate) consists of 15 blunt ended fragments between 100 and 1500 base pairs in multiples of
100 bp.
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Figure 3 Semi-nested PCR products of RAR-P (672 bp) separated on a 2% agarose gel, stained with ethidiumbromide. All cells
were cultivated in a-MEM containing 10tM RA for 4 days. a, HOC-7 (1), HEY (2), H134 (3), HTB 77 (4), HTB 75 (5), 100 bp
DNA ladder (6) OVCAR-3 (7), TR 170 (8), PA-1 (9). (b) Negative RNA control: HOC-7 (1), HEY (2), H134 (3), HTB 77 (4), HTB
75 (5), OVCAR-3 (6), 100 bp DNA ladder (7), TR 170 (8), PA-1 (9), H20 (10). The DNA ladder (ordinate) consists of 15 blunt
ended fragments between 100 and 1500 base pairs in multiples of 100 bp.
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Figure 4 Semi-nested PCR products of RAR-y (498 bp) separated on a 2% agarose gel, stained with ethidiumbromide. a, HOC-7
(1), HEY (2), H134 (3), HTB 77 (4), HTB 75 (5), 100 bp DNA ladder (6) OVCAR-3 (7), TR 170 (8), PA-1 (9). (b) Negative RNA
control: HOC-7 (1), HEY (2), H134 (3), HTB 77 (4), HTB 75 (5), 100 bp DNA ladder (6), OVCAR-3 (7), TR 170 (8), PA-1 (9),
H20 (10). The DNA ladder (ordinate) consists of 15 blunt ended fragments between 100 and 1500 base pairs in multiples of
100 bp.
all-trans RA. All cell lines investigated expressed RAR-x and
-y mRNA under both conditions. Whereas RAR-a and -y
mRNA showed a high baseline expression (Figure 2 and 4),
RAR-P mRNA expression could be demonstrated at a sig-
nificant level only under stimulation with RA; except in
HOC-7 and OVCAR-3 cells where RAR-P mRNA was not
detectable at all (Figure 3; data without RA stimulation of
RAR-P mRNA expression are not shown).
Discussion
Differentiation therapy may become an additional or even
alternative therapeutical approach for the management of
cancer beyond the actual conventional cytotoxic treatment.
Retinoids belong to a group of substances appropriate for
therapeutical use. Since short time retinoids represent the
treatment of choice in acute promyelocytic leukaemia. In534 H. HARANT et al.
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Figure 5 Restriction endonuclease digestion of the RAR-a semi-nested PCR products separated on a 2% agarose gel, stained with
ethidiumbromide (fragments: 127, 237 and 371 bp). HOC-7 (1), HEY (2), HI134 (3), 100 bp DNA ladder (4), HTB 77 (5), HTB 75
(6), OVCAR-3 (7), TR 170 (8), 100 bp DNA ladder (9), PA-i (10). The DNA ladder (ordinate) consists of 15 blunt ended
fragments between 100 and 1500 base pairs in multiples of 100 bp.
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Figure 6 Restriction endonuclease digestion of the RAR-,B semi-
nested PCR products separated on a 2% agarose gel, stained with
ethidiumbromide (fragments: 47, 157 and 468 bp). HEY (1),
H134 (2), HTB 77 (3), 100 bp DNA ladder (4), HTB 75 (5), TR
170 (6), PA-I (7). The DNA ladder (ordinate) consists of 15 blunt
ended fragments between 100 and 1500 base pairs in multiples of
00 bp.
addition, these agents have been successfully used in the
therapy of squamous cell carcinomas and in the prevention
of second primary carcinomas of the aerobronchodigestive
tract (Hong et al., 1990; Lippman et al., 1992).
Although ovarian cancer is a tumour entity responding
moderately well or even well to cytotoxic chemotherapy an
overall 5-year survival of approximately 30-40% is still
unsatisfactory. For this reason our group intended to
evaluate alternative therapeutic strategies for ovarian car-
cinoma, among them induction of differentiation.
The aim of our study was to investigate the effects of RA
and synthetic RA-analogs on the growth of human ovarian
cancer cell lines. The cell lines used in this study have been
characterised previously. They differ clearly in their growth
behaviour and morphology. While HOC-7, HEY, H134 and
PA-1 are rapidly growing cells, the cell lines HTB 77, HTB
75, OVCAR-3 and TR 170 represent a slower growing cell
type (Hamilton et al., 1983; Buick et al., 1985; Hill et al.,
1987; Broxtenman et al., 1987). All epithelial ovarian cancer
cell lines were inhibited in their growth by RA and synthetic
RA-analogs in a dose dependent manner. The cell lines HTB
77, HTB 75, OVCAR-3 and TR 170 were highly responsive
to the retinoids tested, but also the rapidly growing cell lines
HEY and especially H134 were inhibited in their growth by
retinoids. The ovarian adenocarcinoma cell line HOC-7 had
already been used earlier by us as a model for growth
inhibition and differentiation induction by polar-planar com-
pounds like Dimethylsulfoxide and N,N'-dimethylformamide
as well as by transforming growth factor-PI (TGF-1I) and by
all-trans RA. But, all-trans RA caused only a weak growth
inhibition and induction of differentiation associated antigens
in this cell line (Grunt et al., 1992a, 1992b; Somay et al.,
1992). The various retinoids tested in our experiments also
yielded only weak growth inhibition in this cell line. The fact
that both the slowly growing cell lines and the two rapidly
growing cells HEY and H134 were intensively inhibited in
their growth by retinoids led us to conclude that the response
of the epithelial ovarian cancer cell lines to these agents was
not directly dependent on their proliferation capacity. In
contrast, the ovarian teratocarcinoma cell line PA-1 exhibited
a divergent behaviour when treated with these substances.
No growth inhibition, but even a growth promoting effect at
nanomolar concentrations of each retinoid tested was
observed.
Due to the characterisation of the nuclear RARs a better
insight into the mode of action of retinoids on the target cells
was gained. RAR-x seems to be distributed ubiquitously in
cells and tissues, while the expression of RAR-3 and -y
mRNA is tissue-specific (de Luca, 1991). Abnormal expres-
sion of RAR-P mRNA has been reported for some hepatoma
cells and in human oral and epidermal squamous cell car-
cinoma cell lines (Hu et al., 1991). RAR-- mRNA has been
shown to be abundantly expressed in the skin (Krust et al.,
1989). Therefore we wanted to know whether any expression
of RAR mRNA could be detected in the ovarian cancer cell
lines and whether there was a difference in the presence or
absence of RAR subtype mRNA among them. For these
investigations the method of RT-PCR was chosen as a highly
sensitive tool for detecting specific gene transcripts. This
method utilises the cellulary expressed mRNA as templateRETINOIC ACID RECEPTORS IN OVARIAN CANCER CELLS 535
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Figure 7 Restriction endonuclease digestion of the RAR-y semi-nested PCR products separated on a 2% agarose gel, stained with
ethidiumbromide (fragments: 37, 97 and 364 bp). HOC-7 (1), HEY (2), 100 bp DNA ladder (3), HI134 (4), HTB 77 (5), HTB 77 (6),
OVCAR-3 (7), 100 bp ladder (8), TR 170 (9), PA-i (10). The DNA ladder (ordinate) consists of 15 blunt ended fragments between
100 and 1500 base pairs in multiples of 100 bp.
for single-stranded cDNA synthesis that becomes PCR-
amplified subsequently. PCR was performed under stringent
conditions to distinguish between all three receptor subtypes
and PCR products were additionally confirmed by restriction
endonuclease digestion. All cell lines used in this study exp-
ressed RAR-a and -y mRNA, but two of the eight cell lines
failed to express RAR-P transcripts. As reported previously,
RA and synthetic retinoids bind each receptor subtype with
different affinities and cause specific transcriptional activation
of target genes (Astr6m et al., 1990; Graupner et al., 1991).
The lack of RAR-P mRNA in HOC-7 and OVCAR-3 cells
would therefore lead us to expect a similar response of both
cell lines to retinoids, but a divergent behaviour to the
retinoids tested was observed among the two cell lines. On
the other side, the cell line PA-1, which was non-responsive
to the retinoids tested expressed mRNAs for all three recep-
tor subtypes. Overall, we could not observe a conclusive
association between the presence of RAR subtype transcripts
and the response to retinoids in these cell lines. The most
striking finding, that there was a lack of RAR-P transcripts
in two out of eight cell lines, has to be investigated in the
future on the molecular level more in depth. First, by the
method of RT-PCR only a qualitative but not a quantitative
determination of RAR transcripts could be performed which
will be quantified by Northern Analysis and second, rear-
rangements or deletions in the RAR-P gene or other muta-
tional events may be suspected to be the underlaying
mechanism for the observed lack of RAR-P mRNA expres-
sion and will be the target of further investigations (Pratt et
al., 1990; Hu et al., 1991).
We conclude that RA and synthetic retinoids are potent
substances to induce growth inhibition in ovarian cancer
cells. In continuation to these studies the determination of
differentiation associated parameters in retinoid treated
ovarian cancer cells to distinguish between growth inhibition
and differentiation induction and the use of retinoids in
combination with other substances in order to increase their
differentiation capacity are planned.
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